These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 25563216)

  • 1. Long-term follow-up of re-sting reactions in children with moderate to severe venom hypersensitivity.
    Ertoy Karagol HI; Bakirtas A; Yilmaz O; Topal E; Arga M; Demirsoy MS; Turktas I
    Eur J Pediatr; 2015 Jul; 174(7):891-6. PubMed ID: 25563216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy of venom immunotherapy.
    Hafner T; DuBuske L; Kosnik M
    Ann Allergy Asthma Immunol; 2008 Feb; 100(2):162-5. PubMed ID: 18320918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of hymenoptera venom immunotherapy.
    Kayikci H; Bostan OC; Tuncay G; Cihanbeylerden M; Damadoglu E; Karakaya G; Kalyoncu AF
    Allergy Asthma Proc; 2024 Jul; 45(4):268-275. PubMed ID: 38982604
    [No Abstract]   [Full Text] [Related]  

  • 4. Venom immunotherapy for preventing allergic reactions to insect stings.
    Boyle RJ; Elremeli M; Hockenhull J; Cherry MG; Bulsara MK; Daniels M; Oude Elberink JN
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008838. PubMed ID: 23076950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients.
    Lerch E; Müller UR
    J Allergy Clin Immunol; 1998 May; 101(5):606-12. PubMed ID: 9600496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Follow-Up of Children after Venom Immunotherapy: Low Adherence to Anaphylaxis Guidelines.
    Fiedler C; Miehe U; Treudler R; Kiess W; Prenzel F
    Int Arch Allergy Immunol; 2017; 172(3):167-172. PubMed ID: 28380475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
    Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
    Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous venom immunotherapy in children: Efficacy and safety.
    Gür Çetinkaya P; Esenboğa S; Uysal Soyer Ö; Tuncer A; Şekerel BE; Şahiner ÜM
    Ann Allergy Asthma Immunol; 2018 Apr; 120(4):424-428. PubMed ID: 29625665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sting challenge test in Hymenoptera venom allergy: pros and cons.
    Bilò MB; Brianzoni MF; Garritani MS; Antonicelli L; Farabollini B; Bonifazi F
    Eur Ann Allergy Clin Immunol; 2003 Dec; 35(10):377-81. PubMed ID: 14768522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of Hymenoptera venom allergy in children not treated with immunotherapy.
    Lange J; Cichocka-Jarosz E; Marczak H; Krauze A; Tarczoń I; Świebocka E; Lis G; Brzyski P; Nowak-Węgrzyn A
    Ann Allergy Asthma Immunol; 2016 Mar; 116(3):225-9. PubMed ID: 26945496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bee-venom allergy in children: long-term predictive value of standardized challenge tests.
    Schuetze GE; Forster J; Hauk PJ; Friedl K; Kuehr J
    Pediatr Allergy Immunol; 2002 Feb; 13(1):18-23. PubMed ID: 12000494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom.
    Spoerl D; Bircher AJ; Scherer K
    J Investig Allergol Clin Immunol; 2011; 21(1):22-7. PubMed ID: 21370719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exclusive Bee Venom Allergy: Risk Factors and Outcome of Immunotherapy.
    Rosman Y; Nashef F; Cohen-Engler A; Meir-Shafrir K; Lachover-Roth I; Confino-Cohen R
    Int Arch Allergy Immunol; 2019; 180(2):128-134. PubMed ID: 31216540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
    Goldberg A; Confino-Cohen R
    J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of venom immunotherapy on anxiety level of being re-stung].
    Sacha M; Czarnobilska E; Stobiecki M; Dyga W
    Przegl Lek; 2012; 69(12):1261-5. PubMed ID: 23750435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
    Goldberg A; Yogev A; Confino-Cohen R
    Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A twenty-two-year experience with Hymenoptera venom immunotherapy in a US pediatric tertiary care center 1996-2018.
    Albuhairi S; El Khoury K; Yee C; Schneider L; Rachid R
    Ann Allergy Asthma Immunol; 2018 Dec; 121(6):722-728.e1. PubMed ID: 30102964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Ultrarush Venom Immunotherapy: Comparison Between Children and Adults.
    Nittner-Marszalska M; Cichocka-Jarosz E; Małaczyńska T; Kraluk B; Rosiek-Biegus M; Kosinska M; Pawłowicz R; Lis G
    J Investig Allergol Clin Immunol; 2016; 26(1):40-7. PubMed ID: 27012015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
    Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients.
    Wenzel J; Meissner-Kraemer M; Bauer R; Bieber T; Gerdsen R
    Allergy; 2003 Nov; 58(11):1176-9. PubMed ID: 14616130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.